Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line

Biomedicine and Pharmacotherapy

Volumn 66, Issue 8, 2012, Pages 617-626

  Kamran, Mohammed Zahid ^a   Gude, Rajiv P ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

A375 melanoma; Adhesion; Apoptosis; Invasion; Migration; Pentoxifylline; Proliferation

Indexed keywords

ANTIMETASTATIC AGENT; COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; MATRIGEL; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR GROWTH; TUMOR XENOGRAFT; ZYMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MELANOMA; MICE; MICE, SCID; PENTOXIFYLLINE; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869875197     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.03.006     Document Type: Article

References (40)

1. Linos E., Swetter S.M., Cockburn M.G., Colditz G.A., Clarke C.A. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129:1666-1674.
2. Rigel D.S., Russak J., Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010, 60:301-316.
3. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
4. Ward A., Clissold S.P. Pentoxifylline - A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987, 34:50-97.
5. Marzi I., Maier M., Herzog C. Influence of pentoxifylline and albifylline on liver microcirculation and leucocyte adhesion after haemorrhagic shock in the rat. J Trauma 1996, 40:90-96.
6. Gastpar H. The inhibition of cancer cell stickness by the methylxanthine derivative pentoxifylline. Thromb Res 1974, 5:277-289.
7. Lazarczyk M., Grzela T., Niderla J., et al. Differential influence of Pentoxifylline on murine colon adenocarcinoma and melanoma derived metastatic tumor development in lungs. Oncol Rep 2004, 11:1121-1125.
8. Amirkhosravi A., Warnes G., Biggerstaff J., et al. The effect of pentoxifylline on spontaneous and experimental metastasis of the mouse Neuro2a neuroblastoma. Clin Exp Metastasis 1997, 4:453-461.
9. Gude R.P., Ingle A.D., Rao S.G.A. Inhibition on lung homing of B16F10 by Pentoxifylline, microfilament depolymerising agent. Cancer Lett 1996, 106:171-176.
10. Gude R.P., Binda M.M., Prasas H.L., et al. Studies on mechanisms responsible for inhibition of experimental metastasis of B16F10 murine melanoma by pentoxifyllline. J Biomed Sci 1996, 6:133-141.
11. Gude R.P., Binda M.M., Boquete A.L., Bonfil R.D. Inhibition of endothelial cell proliferation and tumor induced angiogenesis by pentoxifylline. J Cancer Res Clin Oncol 2001, 127:625-630.
12. Dua P., Gude R.P. Antiproliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells. Cancer Chemother Pharmacol 2006, 58:195-202.
13. Dua P., Ingle A., Gude R.P. Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma. Int J Cancer 2007, 121:1600-1608.
14. Ribble D., Nathaniel B.G., David A.N., Shellman Y.G. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005, 5:12.
15. Dua P., Gude R.P. Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. Eur J Cancer 2008, 44:1587-1595.
16. Shimul S., Rajiv G. MTA1 aids the AKT pathway by inhibiting expression of a key regulator, PTEN. J Cancer Sci Ther 2010, 2:114-119.
17. Zamarin D., Vigil A., Kelly K., Garcia-Sastre A., Fong Y. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 2009, 16:796-804.
18. Atallah E., Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005, 6:185-193.
19. Tarhini A.A., Agarwala S.S. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006, 19:19-25.
20. Tarhini A.A., Agarwala S.S. Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs 2005, 14:885-892.
21. Zhang M., Yan J.X., Shushma A.M., Amarjit S.A., Naranjan S.D. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol 2004, 9:103-111.
22. Ducloux D., Bresson V.C., Chalopin J. Use of pentoxifylline in membranous nephropathy. Lancet 2001, 357:1672-1673.
23. Yang K., Hitomi M., Stacey D.W. Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Division 2006, 1:32.
24. Lin S.L., Chen R.H., Chen Y.M., et al. Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking AKT membrane translocation. Mol Pharmacol 2003, 64:811-822.
25. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
26. Gahlot S., Khan M.A., Rishi L., Majumdar S. Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Biochem Pharmacol 2010, 80:1650-1661.
27. Pignatelli M., Stamp G. Integrins in tumour development and spread. Cancer Surv 1995, 24:113-127.
28. Shen M.R., Chiang P.H., Yang R.C., Hong C.Y., Chen S.S. Pentoxifylline stimulates human sperm motility both in vitro and after oral therapy. Br J clin Pharmacol 1991, 31:711-714.
29. Elferink J.G., Huizinga T.W., de Koster B.M. The effect of Pentoxifylline on human neutrophil migration: a possible role for cyclic nucleotides. Biochem Pharmacol 1997, 54:475-480.
30. Dominguez-Jimenez C., Sancho D., Nieto M., et al. Effect of Pentoxifylline on polarization and migration of human leucocytes. J Leukoc Biol 2002, 71:588-596.
31. Merighi S., Benini A., Mirandola P., et al. Caffeine inhibits adenosine-induced accumulation of hypoxia inducible factor-1α, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 2007, 72:395-396.
32. Durko M., Navab R., Shibata H.R., Brodt P. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta 1997, 1356:271-280.
33. Ray J.M., Stevenson W.G. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995, 14:908-917.
34. MacDougall J.R., Bani M.R., Lin Y., Rak J., Kerbel R.S. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 1995, 55:4174-4181.
35. Vaisanen A., Tuominen H., Kallioinen M., Turpeenniemi H.T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996, 180:283-289.
36. Hofmann U.B., Westphal J.R., Waas E.T., et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999, 81:774-782.
37. Van den Oord J.J., Paemen L., Opdenakker G., Wolf Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997, 151:665-670.
38. Shellman Y.G., Makelac M., Norrisa D.A. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res 2006, 16:207-211.
39. Ries C., Kolb H., Petrides P.E. Regulation of 92-kD gelatinase release in HL-60 leukemia cells: Tumor Necrosis Factor-a as an autocrine stimulus for basal and phorbol ester induced secretion. Blood 1994, l83:3638-3646.
40. Xie T.X., Wei D., Liu M., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.